Press release
Generalized Anxiety Disorder Market Analysis & Key Trends 2023
Generalized anxiety disorder is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often accompanied by other anxiety disorder, substance abuse, and depression.Report Overview @ https://www.transparencymarketresearch.com/generalized-anxiety-disorder-market.html
Number of factors are responsible to develop GAD which includes genetics, brain chemistry, and environmental factors such as trauma and stressful event, family background, or life experiences. The disorder comes on progressively and can arise across the life cycle, though the risk is highest between childhood and middle age. GAD is diagnosed when a person worries excessively of everyday problems for more than six months and has three or more symptoms. According to Centers for Disease Control and Prevention (CDC), prevalence of anxiety disorder in Europe is over 15 % of total Europe population. In addition, CDC stated that prevalence of disorder is more in women than men. Generally, psychotherapy is preferable to GAD patient before medication which teaches a person different ways of reacting, and thinking in various life situations.
Generalized anxiety disorder market is segmented into therapeutics, and geography. The therapeutics market is segmented into antidepressant, buspirone, and benzodiazepines. Antidepressants further segmented into selective serotonin reuptake inhibitor (SSRI), and serotonin norepinephrine reuptake inhibitor(SNRI). Benzodiazepines includes alprazolam (Niravam, Xanax), chlordiazepoxide (Librium), diazepam (Valium) and lorazepam. However, benzodiazepines can be habit forming hence, generally used for short term basis and consider as a last choice of treatment.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9518
Antidepressant are first line therapy for GAD patient hence, hold the largest market share globally. Geographically, generalized anxiety disorder market segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and Rest of the World (RoW). North America dominates the global generalized anxiety market due to increasing incidence of anxiety disorders, and more awareness in people related to anxiety and it is expected to maintain the position during forecast period. However, Asia Pacific market is expected to grow at a faster rate due to changing lifestyle lead to increasing stress, and growing facilities to detect anxiety disorders.
Some of the major driving factors to propel the generalized anxiety disorders market are increasing incidence rate due to more stressful life, Sedentary lifestyle, and presence of strong pipeline. According to National Institute of Mental Health, every year GAD affects minimum 6.8 million adults, or 3.1% of the U.S. population. In the National Comorbidity Survey carried out in 2005, 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%.
However, poor diagnosis rate as no single diagnosis test is available to detect generalized anxiety disorder, affectivity of psychotherapy, and side effects of medications such as habit forming nature, dry mouth, and nausea could restraint the market growth. Focusing on emerging countries such as BRICS countries would create an opportunity for a market players.
Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=9518<ype=S
Some of the key players of the global generalized anxiety disorder market are Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Baxter International, Bristol-Myers Squibb, Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Recordati Rare Diseases, Noven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma, and Shionogi and Company.
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Generalized Anxiety Disorder Market Analysis & Key Trends 2023 here
News-ID: 913268 • Views: …
More Releases from Transparency Market Research

Lip Augmentation Market Outlook to 2034: Surging to US$ 13.4 Billion on Waves of …
The global lip augmentation market is embarking on a notable growth trajectory, shaped by increasing demand from the entertainment industry, rising social acceptance of aesthetic procedures, and persistent technological innovations in dermal fillers and grafting techniques. Valued at US$ 5.6 billion in 2023, the industry is expected to accelerate at a CAGR of 8.4% from 2024 to 2034, reaching an estimated US$ 13.4 billion by 2034.
Get Sample PDF Brochure from…

Liposomal Supplements Market Outlook to 2034: Steady Growth to US$ 741 Million D …
The liposomal supplements market is on a trajectory of robust and sustained growth, fueled by increasing consumer demand for high-bioavailability nutrition solutions and rapid progress in liposomal delivery systems. In 2023, the global industry was valued at US$ 323.4 million. According to market projections, it will grow at a CAGR of 7.8% from 2024 to 2034, crossing the US$ 741 million mark by the end of 2034. This expansion reflects…

Nucleic Acid Aptamers Market Outlook to 2034: Exploring Robust Growth to US$ 1.2 …
The global nucleic acid aptamers market is undergoing a significant transformation, powered by rapid advancements in biotechnological research and the surging demand for precise diagnostic and therapeutic solutions. Valued at US$ 219.9 million in 2023, the industry is projected to expand at a compelling CAGR of 17.2% between 2024 and 2034, culminating in a market value exceeding US$ 1.2 billion by the end of the forecast period. Several key factors-spanning…

Patient Monitoring and Ultrasound Devices Display Market Forecast 2034: Surge in …
The global patient monitoring and ultrasound devices display market is poised for robust expansion, with the market projected to grow from US$ 5.6 Bn in 2023 to over US$ 10.6 Bn by 2034. Driven by a compound annual growth rate (CAGR) of 5.9% during the forecast period (2024-2034), the sector is undergoing a transformation due to increasing demand for high-resolution diagnostic displays and continuous monitoring systems.
Market Overview: The patient monitoring…
More Releases for GAD
Generalized Anxiety Disorder Pipeline Insight 2025: Advancing Beyond Benzodiazep …
DelveInsight's "Generalized Anxiety Disorder (GAD) - Pipeline Insight, 2025" report offers a deep dive into the emerging therapeutic landscape for GAD, a prevalent and often chronic mental health condition characterized by persistent, excessive worry and associated symptoms like restlessness, fatigue, and sleep disturbances. With traditional treatments such as SSRIs, SNRIs, and benzodiazepines often limited by side effects and variable efficacy, the pipeline is evolving toward novel, targeted, and safer treatment…
Generalized Anxiety Disorder Treatment Market Size in 7MM is expected to grow at …
DelveInsight's " Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Generalized Anxiety Disorder Market Share @ Generalized Anxiety Disorder Market Outlook- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
Generalized Anxiety Disorder Market Set to Grow Substantially Through 2034, Delv …
DelveInsight's "Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Generalized Anxiety Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Generalized Anxiety Disorder…
Generalized Anxiety Disorder Market Report and Forecast 2024-2032
Generalized Anxiety Disorder Market Outlook
The generalized anxiety disorder market size in the 7 major markets was valued at USD 1717.5 million in 2023, driven by the increasing advancements in psychotherapeutic as well as pharmacological treatment options for patients. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to rise from USD 1809.8 million in 2024 to USD 2751.1…
Generalized Anxiety Disorder (GAD) Market: Breakthrough Forecast Study Predicts …
The Generalized Anxiety Disorder (GAD) market is experiencing significant evolution, with a growing recognition of the disorder's prevalence and impact on mental health. Advancements in psychotherapy, pharmacotherapy, and digital health solutions are expanding treatment options and improving outcomes for individuals with Generalized Anxiety Disorder. Additionally, increased awareness and destigmatization efforts are fostering earlier diagnosis and intervention, leading to a more proactive approach to managing Generalized Anxiety Disorder.
DelveInsight's "Generalized Anxiety Disorder…
Generalized Anxiety Disorder Therapeutics Market - From Overwhelm to Empowerment …
Newark, New Castle, USA - new report, titled Generalized Anxiety Disorder Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Generalized Anxiety Disorder Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Generalized Anxiety Disorder Therapeutics market. The report offers…